Lucas Frederik

Nov 22, 2024 | bmccancer.biomedcentral.com | Van Schaik |Van Harten |Lucas Frederik |Ellen Gurumay

In total, 19 stakeholders were interviewed from seven different regions in the Netherlands. The stakeholder group ‘molecular specialists’ consisted of three pathologists and four respondents who were either a molecular biologist in pathology or a laboratory specialist in clinical genetics (Table 2). The ‘medical specialists’ group consisted of four medical oncologists, one pulmonologist and two clinical geneticists.